PHARMACODYNAMICS AND PHARMACOKINETICS OF 2 GLIBENCLAMIDE PREPARATIONS IN TYPE-II DIABETES - INTRAINDIVIDUAL DOUBLE-BLIND COMPARISON OF EUGLUCON-5(HB 419) AND EUGLUCON-N(HB 420)

被引：9

作者：

HAUPT, E

PUTSCHKY, F

ZOLTOBROCKI, M

SCHOFFLING, K

机构：

[1] HOECHST AG,KLIN FORSCH ABT,D-6280 FRANKFURT,FED REP GER

[2] UNIV FRANKFURT KLINIKUM,ZENTRUM INNERE MED,ENDOCRINOL ABT,D-6000 FRANKFURT 70,FED REP GER

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 1984年 / 109卷 / 06期

关键词：

D O I：

10.1055/s-2008-1069168

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：210 / 213

页数：4

共 24 条

[1]

CHANDALIA HB, 1969, HORMONE METAB RES S, V1, P73

[2]

CHRIST OE, 1969, HORMONE METABOLIC S, V1, P51

[3] INSULINOTROPIC EFFECTS OF HYPOGLYCEMIC AND HYPERGLYCEMIC SULFONAMIDES - THE IONOPHORETIC HYPOTHESIS [J].

COUTURIER, E ;

MALAISSE, WJ .

DIABETOLOGIA, 1980, 19 (04) :335-340

[4] SULFONYLUREA (GLIBENCLAMIDE) ENHANCES SOMATOSTATIN AND INHIBITS GLUCAGON-RELEASE INDUCED BY ARGININE [J].

EFENDIC, S ;

ENZMANN, F ;

NYLEN, A ;

UVNASWALLENSTEN, K ;

LUFT, R .

ACTA PHYSIOLOGICA SCANDINAVICA, 1980, 108 (03) :231-233

[5] SULFONYLUREAS INCREASE NUMBER OF INSULIN RECEPTORS [J].

FEINGLOS, MN ;

LEBOVITZ, HE .

NATURE, 1978, 276 (5684) :184-185

[6] CELL-RECEPTOR DEFECTS AS THE CAUSE OF ENDOCRINE AND METABOLIC DISEASES [J].

GEROK, W .

KLINISCHE WOCHENSCHRIFT, 1979, 57 (12) :613-623

[7] GLIBENCLAMIDE-INSULIN COMBINATION IN THE MANAGEMENT OF SECONDARY FAILURE OF SULFONYL-UREA MEDICATION [J].

HAMELBECK, H ;

KLEIN, W ;

ZOLTOBROCKI, M ;

SCHOFFLING, K .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1982, 107 (42) :1581-1583

[8]

HAPP J, 1974, ARZNEIMITTELFORSCH, V24, P1228

[9]

HAUPT E, 1977, DEUT MED WOCHENSCHR, V102, P1070

[10] PHARMACODYNAMIC ASPECTS OF TOLBUTAMIDE, GLIBENCLAMIDE, GLIBORNURIDE, AND GLISOXEPIDE .2. REPEATED ADMINISTRATION IN COMBINATION WITH GLUCOSE [J].

HAUPT, E ;

BEYER, J ;

SCHOFFLING, K ;

KOBERICH, W .

DIABETOLOGIA, 1971, 7 (06) :455-+

← 1 2 3 →